Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Cystic Fibrosis | PREDICT | National Jewish [Lead]
Previous Study | Return to List | Next Study

PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis (PREDICT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02073409
Recruitment Status : Recruiting
First Posted : February 27, 2014
Last Update Posted : June 24, 2019
Sponsor:
Collaborators:
Cystic Fibrosis Foundation
Children's Hospital Colorado
Information provided by (Responsible Party):
Jerry A. Nick, M.D., National Jewish Health

Brief Summary:
Isolation of nontuberculous mycobacteria (NTM) from the sputum of individuals with CF is an increasingly common finding, and the lack of an evidenced-based approach to the diagnosis of NTM disease has been identified as one of the greatest unmet needs within the CF community. Current evidence predicts that the prevalence of NTM will remain relatively high in the CF population. Approaches to NTM disease diagnosis differ widely between centers. This study is observational and follows current best practices. The study will help standardize the diagnosis and collect relevant data associated with the diagnosis of NTM disease to build a framework for future therapeutic trials.

Condition or disease
Cystic Fibrosis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Study Start Date : December 2013
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023


Group/Cohort
CF patients
Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.



Primary Outcome Measures :
  1. Proportion meeting the diagnosis of NTM disease [ Time Frame: 12 months intervals following study enrollment ]

Secondary Outcome Measures :
  1. Adherence to PREDICT protocol: number of respiratory cultures obtained per participant per year, withdrawals and major deviations from protocol [ Time Frame: 12 months intervals following study enrollment ]
  2. Incidence and prevalence of NTM species/subspecies by geographical region [ Time Frame: 12 months intervals following study enrollment ]
  3. Proportion of eligible NTM positive individuals with CF enrolling in PREDICT by site [ Time Frame: 12 months intervals following study enrollment ]
  4. Proportion of PREDICT participants with NTM disease diagnosis who enroll in Part B PATIENCE [ Time Frame: 12 months intervals following study enrollment ]
  5. Clinical parameters and outcomes (FEV1, growth parameters, CFQ-R) [ Time Frame: 12 months intervals following study enrollment ]

Biospecimen Retention:   Samples Without DNA
Samples collected may include serum, sputum, whole blood, breath, urine, and NTM isolates.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
Criteria

Inclusion Criteria:

  1. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative
  2. Enrolled in the CFF Patient Registry (CFF PR)
  3. Be willing and able to adhere to study procedures in the context of clinical care, and other protocol requirements
  4. Male or female participant ≥ 6 years of age at enrollment who are able to reliably expectorate sputum and/or willing to undergo sputum induction (if necessary)
  5. Diagnosis of CF consistent with the 2017 CFF Guidelines
  6. NTM positive for a species or sub-species in the 2 years prior to enrollment that has never been treated.
  7. Willing to discontinue chronic azithromycin use for the duration of the study

Exclusion Criteria:

  1. Prior or ongoing antibiotic treatment of the same NTM species or sub-species for which the patient is being considered for this study
  2. History of solid organ or hematological transplantation
  3. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02073409


Contacts
Layout table for location contacts
Contact: Marion Jones, RN (303) 398-1265 jonesm@njhealth.org
Contact: Meg Anthony, MSW (720) 777-2945 Meg.Anthony@childrenscolorado.org

Locations
Layout table for location information
United States, Alabama
CFF Pediatric Program, University of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Contact: Katie Brand    205-638-9410    kbrand@peds.uab.edu   
Principal Investigator: George M Solomon, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Meg Anthony, MSW    720-777-2945    Meg.Anthony@childrenscolorado.org   
Principal Investigator: Stacey Martiniano, MD         
National Jewish Health Recruiting
Denver, Colorado, United States, 80206
Contact: Sarah Ellington, RN    303-270-2333    ellingtons@njhealth.org   
Principal Investigator: Jerry A Nick, MD         
United States, Maryland
CFF Adult Program, Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21205
Contact: Mary Rykiel    410-614-1409    mrykiel1@jhmi.edu   
Principal Investigator: Keira Cohen, MD         
United States, Michigan
CFF Pediatric Program University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Dawn Kruse    734-615-3266    dmkruse@med.umich.edu   
Principal Investigator: Lindsay Caverly, MD         
United States, New York
CFF Pediatric Program, Columbia University Recruiting
New York, New York, United States, 10032
Contact: Amanda Kramer    215-305-4675    ARK2187@columbia.edu   
Principal Investigator: Emily DiMango, MD         
United States, North Carolina
CFF Adult Program, University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27517
Contact: Kelsey Haywood    919-445-2855    kelsey_haywood@med.unc.edu   
Principal Investigator: Jennifer Goralski, MD         
United States, Texas
CFF Adult Program, The University of Texas Southwestern Medical Center at Dallas Recruiting
Dallas, Texas, United States, 75390-8558
Contact: Ashley Keller    214-648-2817    Ashley.Keller@UTSouthwestern.edu   
Principal Investigator: Raksha Jain, MD         
United States, Washington
CFF Pediatric Program Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Sharon McNamara    206-987-3921    sharon.mcnamara@seattlechildrens.org   
Principal Investigator: Ronald Gibson, MD         
CFF Adult Program, University of Washington Recruiting
Seattle, Washington, United States, 98195
Contact: Teresa Gambol    206-543-7382    TGambol@medicine.washington.edu   
Principal Investigator: Moira Aitken, MD         
Sponsors and Collaborators
National Jewish Health
Cystic Fibrosis Foundation
Children's Hospital Colorado
Investigators
Layout table for investigator information
Principal Investigator: Jerry A Nick, MD National Jewish Health
Principal Investigator: Stacey Martiniano, MD Children's Hospital Colorado

Layout table for additonal information
Responsible Party: Jerry A. Nick, M.D., Professor of Medicine, National Jewish Health
ClinicalTrials.gov Identifier: NCT02073409     History of Changes
Other Study ID Numbers: NTM-OB-17 (PREDICT PART A)
First Posted: February 27, 2014    Key Record Dates
Last Update Posted: June 24, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jerry A. Nick, M.D., National Jewish Health:
Nontuberculous Mycobacteria
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases